No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 21
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Damora Therapeutics, Inc. (DMRA) stock was $19.50 as of Oct 6, 2026, 10:00 AM EDT, down 3.56% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +429.3% · 3-year avg +8.1%/yr · 5-year avg -25.1%/yr
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.
Biotechnology · Waltham, MA
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
-0.48
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.39
vs Estimate
$-0.41
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1DMRA | $1.20B | $19.50 | -3.56% | +429.27% | -25.05% | N/A | N/A |
| 2INNV | $1.22B | $9.00 | N/A | +79.14% | +5.55% | N/A | vs DMRA |
| 3MNKD | $1.22B | $3.83 | +0.13% | -33.55% | -4.18% | +1.97% | vs DMRA |
| 4CRON | $1.22B | $3.27 | +0.77% | +25.83% | -9.92% | +13.62% | vs DMRA |
| 5AVLN | $1.17B | $26.33 | -2.59% | N/A | N/A | N/A | vs DMRA |
| 6GDRX | $1.16B | $3.35 | -0.45% | -25.72% | -39.98% | N/A | vs DMRA |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 9 analysts
Average Price Target
$46.89
+140.5% upside
Low
$40.00
Current
$19.50
High
$60.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.65 | $-0.48 | $-0.34 | 3 |
| Quarter ending Dec 2026 | $-0.58 | $-0.51 | $-0.40 | 3 |
| Quarter ending Mar 2027 | $-0.49 | $-0.49 | $-0.49 | 1 |
| Quarter ending Jun 2027 | $-0.50 | $-0.50 | $-0.50 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-2.26 | $-2.04 | $-1.65 | 5 |
| FY 2027 | $-2.84 | $-2.11 | $-1.57 | 5 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $0.00 | $0.00 | $0.00 | 0 |
| FY 2027 | $0.00 | $0.00 | $0.00 | 0 |
